B-Cell Manifestations in Chronic Lymphocytic Leukemia
In CLL, B-cell-related manifestations present both clinically and physically through lymphocytosis with characteristic small mature lymphocytes, lymphadenopathy, hepatosplenomegaly, autoimmune cytopenias, hypogammaglobulinemia with recurrent infections, and the distinctive immunophenotype CD5+/CD19+/CD20+/CD23+ on flow cytometry.
Clinical Manifestations
Hematologic Features
The hallmark clinical finding is sustained peripheral blood lymphocytosis ≥5000 monoclonal B lymphocytes/µL that must persist for at least 3 months 1, 2. Blood smears reveal small, mature-appearing lymphocytes with narrow cytoplasm borders, dense nuclei lacking discernible nucleoli, and partially aggregated chromatin 1. Larger atypical lymphocytes or prolymphocytes may appear but must not exceed 55% 1.
Immunophenotypic Signature
Flow cytometry demonstrates the pathognomonic B-cell pattern: co-expression of CD5 (normally a T-cell antigen) with B-cell markers CD19, CD20, and CD23 1, 2, 3. Critically, surface immunoglobulin, CD20, and CD79b levels are characteristically dim or low compared to normal B cells 1, 2. Each clone shows restriction to either kappa or lambda light chains, confirming monoclonality 1, 2.
Autoimmune Complications
Autoimmune cytopenias occur in 5-10% of CLL patients, with autoimmune hemolytic anemia (AIHA) being most common 4. These patients require direct antiglobulin (Coombs) testing 1. The prognosis for autoimmune cytopenia is notably better than cytopenia from massive bone marrow infiltration 4. Most respond to corticosteroids 4.
Immune Deficiency
Severe immune defects develop during disease course, manifesting as:
- Hypogammaglobulinemia requiring serum immunoglobulin measurement 1
- Recurrent infections as a common complication 4, 5, 4
- Increased susceptibility despite prophylactic intravenous immunoglobulin not improving overall survival 4
Physical Manifestations
Lymphoid Organ Involvement
Physical examination reveals:
- Lymphadenopathy: Multiple enlarged lymph node regions are characteristic. The Binet staging system specifically categorizes disease by number of involved lymph node areas (<3 regions = stage A; ≥3 regions = stage B) 1, 2
- Splenomegaly: The most consistent physical finding, detected in 40-50% of cases 6
- Hepatomegaly: Less common than splenomegaly 6
Symptomatic Presentations
When symptomatic (approximately 30% at diagnosis 6), patients experience:
- B-symptoms: Fever, drenching night sweats, weight loss 3
- Fatigue and malaise from anemia 6
- Left upper quadrant fullness or pain from splenomegaly 6
- Rare manifestations include bleeding (thrombocytopenia/dysfunction), thrombosis (thrombocytosis/marked leukocytosis), and gouty arthritis (elevated uric acid) 6
Bone Marrow Findings
While bone marrow biopsy is not required for diagnosis 1, 2, when performed it shows:
- Increased cellularity from myelopoiesis proliferation
- Small, mature lymphocyte infiltration
- Diffuse or nodular patterns (though this no longer has prognostic significance with modern markers) 7
- Moderate to marked reticulin fibrosis in 30% of cases 6
Critical Diagnostic Pitfalls
Differential diagnosis is essential: CLL must be distinguished from mantle cell lymphoma (which typically lacks CD23 expression despite being CD5+) 2, 8, marginal zone lymphoma, and immunocytoma 2. Mantle cell lymphoma requires FISH for t(11;14) translocation and cyclin D1 staining 3, 8, 3.
Transformation risk: 2-15% of patients develop Richter's syndrome (transformation to aggressive lymphoma) or B-cell prolymphocytic leukemia during disease course, requiring lymph node excision for confirmation 4.
The constellation of these B-cell manifestations—from the characteristic immunophenotype to physical lymphoid organ involvement and immune dysfunction—defines the clinical presentation of CLL and guides both staging and treatment decisions.